A statistical virtual patient population for the glucoregulatory system in type 1 diabetes with integrated exercise model
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 7 of the 23 sources its claims cite were checked for support.
Abstract
PURPOSE: We introduce two validated single (SH) and dual hormone (DH) mathematical models that represent an in-silico virtual patient population (VPP) for type 1 diabetes (T1D). The VPP can be used to evaluate automated insulin and glucagon delivery algorithms, so-called artificial pancreas (AP) algorithms that are currently being used to help people with T1D better manage their glucose levels. We present validation results comparing these virtual patients with true clinical patients undergoing AP control and demonstrate that the virtual patients behave similarly to people with T1D. METHODS: A single hormone virtual patient population (SH-VPP) was created that is comprised of eight differential equations that describe insulin kinetics, insulin dynamics and carbohydrate absorption. The parameters in this model that represent insulin sensitivity were statistically sampled from a normal distribution to create a population of virtual patients with different levels of insulin sensitivity. A dual hormone virtual patient population (DH-VPP) extended this SH-VPP by incorporating additional equations to represent glucagon kinetics and glucagon dynamics. The DH-VPP is comprised of thirteen differential equations and a parameter representing glucagon sensitivity, which was statistically sampled from a normal distribution to create virtual patients with different levels of glucagon sensitivity. We evaluated the SH-VPP and DH-VPP on a clinical data set of 20 people with T1D who participated in a 3.5-day outpatient AP study. Twenty virtual patients were matched with the 20 clinical patients by total daily insulin requirements and body weight. The identical meals given during the AP study were given to the virtual patients and the identical AP control algorithm that was used to control the glucose of the virtual patients was used on the clinical patients. We compared percent time in target range (70-180 mg/dL), time in hypoglycemia (<70 mg/dL) and time in hyperglycemia (>180 mg/dL) for both the virtual patients and the actual patients. RESULTS: The subjects in the SH-VPP performed similarly vs. the actual patients (time in range: 78.1 ± 5.1% vs. 74.3 ± 8.1%, p = 0.11; time in hypoglycemia: 3.4 ± 1.3% vs. 2.8 ± 1.7%, p = 0.23). The subjects in the DH-VPP also performed similarly vs. the actual patients (time in range: 75.6 ± 5.5% vs. 71.9 ± 10.9%, p = 0.13; time in hypoglycemia: 0.9 ± 0.8% vs. 1.3 ± 1%, p = 0.19). While the VPPs tended to over-estimate the time in range relative to actual patients, the difference was not statistically significant. CONCLUSIONS: We have verified that a SH-VPP and a DH-VPP performed comparably with actual patients undergoing AP control using an identical control algorithm. The SH-VPP and DH-VPP may be used as a simulator for pre-evaluation of T1D control algorithms.
Overview
CoChat Summary
TL;DR
The paper presents single-hormone and dual-hormone virtual patient populations for type 1 diabetes, built from glucoregulatory models with statistically sampled insulin and glucagon sensitivity parameters and an integrated aerobic exercise model. When matched to 20 clinical patients by total daily insulin requirement and weight and run under identical meals and the same artificial pancreas controller, the virtual populations showed no statistically significant differences in key glycemic outcomes.
Key findings
- The single-hormone VPP performed similarly to actual patients: time in range 78.1 ± 5.1% vs. 74.3 ± 8.1% (p = 0.11), and time in hypoglycemia 3.4 ± 1.3% vs. 2.8 ± 1.7% (p = 0.23).
- The dual-hormone VPP also performed similarly to actual patients: time in range 75.6 ± 5.5% vs. 71.9 ± 10.9% (p = 0.13), and time in hypoglycemia 0.9 ± 0.8% vs. 1.3 ± 1% (p = 0.19).
- Time in hyperglycemia was not significantly different for SH-VPP (18.4 ± 5.3% vs. 22.9 ± 8.8%, p = 0.08) or DH-VPP (23.5 ± 5.7% vs. 26.7 ± 11.4%, p = 0.21).
- In a comparison across 10 selected meal scenarios, the SH-VPP had lower mean absolute error for time in range relative to clinical data than the UVA/Padova simulator (15.8% vs. 33.4%).
Methods
- The SH-VPP used eight differential equations for insulin kinetics, insulin dynamics, and carbohydrate absorption; the DH-VPP extended this to thirteen equations by adding glucagon kinetics and dynamics. Insulin sensitivity factors (Sf1, Sf2, Sf3) were statistically sampled for the SH-VPP; glucagon sensitivity and related parameters were also sampled for the DH-VPP.
- Validation used clinical data from 20 people with T1D in two separate 3.5-day randomized outpatient artificial pancreas trials, with meals, daily activities, and in-clinic aerobic exercise at 60% of maximal VO2. Twenty virtual patients were matched to the 20 clinical patients by closest total daily insulin requirement and weight.
- The identical meals and the same OHSU-FMPD control algorithm were applied to virtual patients, with ±30% meal uncertainty, circadian insulin sensitivity variability, and CGM noise modeled. Outcomes were compared using two-tailed t-tests at a 5% significance level, with mean absolute error reported.
Limitations
- The paper states that meal amount was estimated rather than known, rescue carbohydrate timing was uncertain, circadian insulin sensitivity variability was modeled approximately, the exercise model assumed 50% active muscular mass for all subjects, and CGM noise was based on the Dexcom G4 sensor while clinical data used the Dexcom G5.
- The paper states that mean absolute error was higher than preferred for time in range and time in hyperglycemia, indicating imperfect individual-level matching.
- Evident from the text: validation used only one control algorithm and a relatively small clinical sample of 20 patients, so generalizability to other controllers or larger populations is not directly established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
6 Valid · 2 Not valid · 11 Not checked · 40 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“These virtual populations were validated against clinical data acquired from real-world patients with T1D [12].”
§ A statistical virtual patient population for the glucoregulatory system in type 1 diabetes with integrated exercise model > Discussion and conclusion
What the sources say
- Could not verifycites [12] JR Castle, 2018, Randomized Outpatient Trial of Single- and Dual-Hormone Closed-Loop Systems That Adapt to Exercise Using Wearable Sensors, Diabetes care sourceExperimental — accuracy not yet measured
The Participants and Study Design and Procedures sections describe a trial involving adults with type 1 diabetes, not two virtual patient populations. A search for virtual populations, simulation, and validation against clinical data found no passage addressing the claimed validation. (LLM, conf=0.75)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“Since insulin is known to vary during the day [24], circadian variability of insulin sensitivity was introduced to the insulin sensitivity parameters (Sf1, Sf2 and Sf3) within each virtual patient by varying these parameters with respect to time of day using Eq (12):”
- Also stated in: § Discussion and conclusion · plain
“Third, it is known that insulin sensitivity can vary throughout the day.”
§ A statistical virtual patient population for the glucoregulatory system in type 1 diabetes with integrated exercise model > Materials and methods > Validating VPPs under real-world meal scenarios
What the sources say
- Supportedcites [24] P Herrero, 2017, Enhancing automatic closed-loop glucose control in type 1 diabetes with an adaptive meal bolus calculator—in silico evaluation under intra-day variability, Computer methods and programs in biomedicine source
In Materials and Methods, under “Intra-day variability,” the paper says insulin sensitivity parameters were assumed to vary throughout the day in a sinusoidal pattern. This supports the attributed point that insulin sensitivity varies with time of day, though the passage describes an assumption used in the simulation. (LLM, conf=0.89)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion and conclusion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For all outcome measures, the SH-VPP was not statistically different than the true population.”
§ A statistical virtual patient population for the glucoregulatory system in type 1 diabetes with integrated exercise model > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The MAE of time spent in hyperglycemia was high for SH-VPP showing that the meal model should be further improved to better represent glucose levels above 180 mg/dl.”
§ A statistical virtual patient population for the glucoregulatory system in type 1 diabetes with integrated exercise model > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, they misestimated the time in hypoglycemia compared to the clinical data.”
§ A statistical virtual patient population for the glucoregulatory system in type 1 diabetes with integrated exercise model > Discussion and conclusion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
30 more claims
Create a free account to see all 59 claims and to verify the 2 references still open.
- Probably not a substantial claim. 15
- It may state two separate claims as one. 9
- The quote only partly states this claim. 1
Citations
Cites
Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes
Hovorka, R., Canonico, V., Chassin, L. J., Haueter, U., Massi-Benedetti, M., Federici, M. O., Pieber, T. R., Schaller, H. C., Schaupp, L., Vering, T., et al. (2004) · Physiological Measurement · doi:10.1088/0967-3334/25/4/010 · Cited by 1,274
Exercise management in type 1 diabetes: a consensus statement
Riddell, M. C., Gallen, I. W., Smart, C. E., Taplin, C. E., Adolfsson, P., Lumb, A. N., Kowalski, A., Rabasa-Lhoret, R., McCrimmon, R. J., Hume, C., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30014-1 · Cited by 903
The UVA/PADOVA Type 1 Diabetes Simulator: New Features
Man, C. D., Micheletto, F., Lv, D., Breton, M., Kovatchev, B., & Cobelli, C. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296813514502 · Cited by 791
In Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes
Kovatchev, B. P., Breton, M., Dalla Man, C., & Cobelli, C. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300106 · Cited by 760
Simulation Environment to Evaluate Closed-Loop Insulin Delivery Systems in Type 1 Diabetes
Wilinska, M. E., Chassin, L. J., Acerini, C. L., Allen, J. M., Dunger, D. B., & Hovorka, R. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400117 · Cited by 244
Castle, J. R., El Youssef, J., Wilson, L. M., Reddy, R., Resalat, N., Branigan, D., Ramsey, K., Leitschuh, J., Rajhbeharrysingh, U., Senf, B., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0228 · Cited by 152
Self-citationModeling the glucose sensor error
Facchinetti, A., Del Favero, S., Sparacino, G., Castle, J. R., Ward, W. K., & Cobelli, C. (2014) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2013.2284023 · Cited by 130
Jacobs, P. G., El Youssef, J., Reddy, R., Resalat, N., Branigan, D., Condon, J., Preiser, N., Ramsey, K., Jones, M., Edwards, C., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12707 · Cited by 116
Self-citationJacobs, P. G., Resalat, N., El Youssef, J., Reddy, R., Branigan, D., Preiser, N., Condon, J., & Castle, J. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815609371 · Cited by 105
Self-citationWalsh, J., Roberts, R., & Bailey, T. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400516 · Cited by 103
Visentin, R., Dalla Man, C., Kovatchev, B., & Cobelli, C. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0377 · Cited by 103
Visentin, R., Man, C. D., & Cobelli, C. (2016) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2016.2535241 · Cited by 86
Jacobs, P. G., El Youssef, J., Castle, J., Bakhtiani, P., Branigan, D., Breen, M., Bauer, D., Preiser, N., Leonard, G., Stonex, T., et al. (2014) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2014.2323248 · Cited by 82
Self-citationZakeri, I., Adolph, A. L., Puyau, M. R., Vohra, F. A., & Butte, N. F. (2008) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01163.2007 · Cited by 80
Facchinetti, A., Del Favero, S., Sparacino, G., & Cobelli, C. (2015) · Medical & Biological Engineering & Computing · doi:10.1007/s11517-014-1226-y · Cited by 80
An Insulin Infusion Advisory System Based on Autotuning Nonlinear Model-Predictive Control
Zarkogianni, K., Vazeou, A., Mougiakakou, S. G., Prountzou, A., & Nikita, K. S. (2011) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2011.2157823 · Cited by 80
Percival, M. W., Wang, Y., Grosman, B., Dassau, E., Zisser, H., Jovanovič, L., & Doyle, F. J. (2011) · Journal of Process Control · doi:10.1016/j.jprocont.2010.10.003 · Cited by 75
Haidar, A., Wilinska, M. E., Graveston, J. A., & Hovorka, R. (2013) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2013.2272736 · Cited by 69
Herrero, P., Bondia, J., Adewuyi, O., Pesl, P., El-Sharkawy, M., Reddy, M., Toumazou, C., Oliver, N., & Georgiou, P. (2017) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2017.05.010 · Cited by 63
Facchinetti, A., Favero, S., Sparacino, G., & Cobelli, C. (2013) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2012.2227256 · Cited by 62
Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine
McCall, A. L., Cox, D. J., Brodows, R., Crean, J., Johns, D., & Kovatchev, B. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0107 · Cited by 46
Hernández-Ordoñez, M., & Campos-Delgado, D. U. (2008) · Journal of Biomechanics · doi:10.1016/j.jbiomech.2007.11.028 · Cited by 43
Personalizing physical exercise in a computational model of fuel homeostasis
Palumbo, M. C., Morettini, M., Tieri, P., Diele, F., Sacchetti, M., & Castiglione, F. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006073 · Cited by 36
MODELING EXERCISE EFFECTS IN TYPE I DIABETIC PATIENTS
Lenart, P. J., & Parker, R. S. (2002) · IFAC Proceedings Volumes · doi:10.3182/20020721-6-es-1901.01350 · Cited by 34
Design of a dual-hormone model predictive control for artificial pancreas with exercise model
Resalat, N., El Youssef, J., Reddy, R., & Jacobs, P. G. (2016) · 2016 38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc.2016.7591182 · Cited by 34
Self-citationA Novel Adaptive Basal Therapy Based on the Value and Rate of Change of Blood Glucose
Wang, Y., Percival, M. W., Dassau, E., Zisser, H., Jovanovic, L. G., & Doyle, F. J. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300513 · Cited by 25
Rickels, M. R., Kong, S. M., Fuller, C., Dalton-Bakes, C., Ferguson, J. F., Reilly, M. P., Teff, K. L., & Naji, A. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00667.2013 · Cited by 16
Resalat, N., Youssef, J. E., Reddy, R., & Jacobs, P. G. (2017) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2017.08.2270 · Cited by 15
Self-citation
Cited by
Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era
Akil, A. A.-S., Yassin, E., Al-Maraghi, A., Aliyev, E., Al-Malki, K., & Fakhro, K. A. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02778-6 · Cited by 168
“The hyperglycemia or hypoglycemia causes identification performed through validated single and dual hormone mathematical models that demonstrate a virtual platform of T1D patients [109].”
BackgroundAn artificial intelligence decision support system for the management of type 1 diabetes
Tyler, N. S., Mosquera-Lopez, C. M., Wilson, L. M., Dodier, R. H., Branigan, D. L., Gabo, V. B., Guillot, F. H., Hilts, W. W., El Youssef, J., Castle, J. R., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0212-y · Cited by 163
Self-citationEnvisioning the Future of Personalized Medicine: Role and Realities of Digital Twins
Vallée, A. (2024) · Journal of Medical Internet Research · doi:10.2196/50204 · Cited by 201
“In a similar vein, endeavors have been made to craft digital patients with precise measurements, such as glucose levels, either through mathematical models [62] or by incorporating highly specific attributes [81].”
BackgroundJacobs, P. G., Herrero, P., Facchinetti, A., Vehi, J., Kovatchev, B., Breton, M. D., Cinar, A., Nikita, K. S., Doyle, F. J., Bondia, J., et al. (2024) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2023.3331297 · Cited by 113
Self-citationArtificial Intelligence in Decision Support Systems for Type 1 Diabetes
Tyler, N. S., & Jacobs, P. G. (2020) · Sensors · doi:10.3390/s20113214 · Cited by 93
“While these dynamic models can be used to forecast glycemic outcomes [15,26,27], many of these physical models have been developed to simulate the glucose dynamics of T1D populations [28,29] and to design and evaluate DSS algorithms [19].”
MethodSelf-citation
Metadata
- Authors
- Resalat, N., El Youssef, J., Tyler, N., Castle, J., & Jacobs, P. G.
- Affiliations
- Oregon Health & Science University (US)
- Corresponding author
- Jacobs, Peter G.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2019-07-25
- Volume
- 14
- Issue
- 7
- Pages
- e0217301
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC6657828
- OpenAlex
- W2963898471
- Semantic Scholar
- 2ed50a04c433e06a870d929d0948c3de3cdeaebd
- Cited by
- 78
- References
- 28
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 10 · 2023: 19 · 2022: 8 · 2021: 11 · 2020: 10 · 2019: 2
- FWCI
- 6.29
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (1DP3DK101044)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 1 diabetes, virtual patient population, artificial pancreas, closed-loop glucose control, insulin kinetics, exercise model, insulin sensitivity, glucagon sensitivity, glucose homeostasis, time in range, hypoglycemia, hyperglycemia, carbohydrate absorption
- MeSH terms
- Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 1, Female, Glucagon, Humans, Insulin, Kinetics, Male, Middle Aged, Models, Biological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.